Table 2. Comparison of inflammatory vs. fibrostenotic phenotype.

	All patients (n=256)	P-value	Pediatric (n=64)	P-value	Adults (n=191)	P-value
	Inflammatory vs. fibrostenosis		Inflammatory vs. fibrostenosis		Inflammatory vs. fibrostenosis
Demographics
Age (years±s.d.)	24±19 vs. 39±15	<0.001	8±5 vs. 11±4	0.046	38±15 vs. 41±14	0.179
% Male	74 vs. 75 (%)	0.774	83 vs. 100 (%)	0.333	65 vs. 83 (%)	0.241
% Caucasian	87 vs. 90 (%)	0.556	87 vs. 90 (%)	1.000	87 vs. 90 (%)	0.627
Atopic conditions
Asthma	33 vs. 23 (%)	0.121	46 vs. 30 (%)	0.492	21 vs. 23 (%)	0.853
Food allergies	41 vs. 25 (%)	0.007	69 vs. 40 (%)	0.148	18 vs. 24 (%)	0.356
Eczema	22 vs. 11 (%)	0.017	43 vs. 20 (%)	0.292	5 vs. 10 (%)	0.272
Allergic rhinitis	52 vs. 38 (%)	0.032	65 vs. 80 (%)	0.476	41 vs. 35 (%)	0.430
Clinical presentation
Dysphagia	67 vs. 92 (%)	<0.001	48 vs. 70 (%)	0.305	84 vs. 94 (%)	0.037
Food impaction	30 vs. 46 (%)	0.010	19 vs. 80 (%)	<0.001	40 vs. 44 (%)	0.755
Heartburn	30 vs. 40 (%)	0.115	13 vs. 30 (%)	0.189	45 vs. 41 (%)	0.639
Regurgitation	36 vs. 27 (%)	0.248	40 vs. 40 (%)	1.000	30 vs. 25 (%)	0.654
Symptom characteristics
Symptom improvement over time	60 vs. 69 (%)	0.256	70 vs. 80 (%)	0.784	52 vs. 68 (%)	0.024
Duration of symptoms (years±s.d.)	5.3±6.3 vs. 8.1±7.7	0.002	3.5±3.4 vs. 3.7±2.4	0.818	6.9±7.7 vs. 8.5±7.8	0.201
Follow-up time (years±s.d.)	1.6±2.0 vs. 1.7±1.9	0.442	1.0±1.2 vs. 0.7±0.9	0.466	2.0±2.4 vs. 1.8±1.9	0.497
Disease characteristics
Grade 3 mid-proximal eosinophilia (≥15 eos/hpf)	82 vs. 79 (%)	0.769	87 vs. 90 (%)	0.726	77 vs. 78 (%)	0.606
Grade 3 distal eosinophilia (≥15 eos/hpf)	89 vs. 88 (%)	0.359	91 vs. 100 (%)	0.636	86 vs. 88 (%)	0.441
% Patients underwent dilation	9 vs. 44 (%)	<0.001